Related-Party Transactions |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Related-Party Transactions [Abstract] | |
| Related-Party Transactions | (11) Related‑Party
Transactions In November 2023, the
Company issued unsecured convertible notes and accompanying Series A and Series
B Warrants (see Note 8).
The transaction included the issuance of a $5 million convertible note and
Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO,
President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on
the Company’s board of directors. The Series B Warrants expired in . In November 2024, the Company paid PharmaCyte accrued interest on the
convertible note of $300,000 in equity comprising 315,790 common
shares. In addition, during the
year ended December 31, 2024 and three months ended March 31, 2025, a family
member of the CEO was employed by the Company.
|